Abstract
Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA).Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential baseline parameters influencing persistence on treatment were also evaluated.Methods: PsA patients from 16 Italian Rheumatology Units treated with adalimumab as first- or second-line biological therapy were retrospectively evaluated. Adalimumab retention rate was evaluated at 12 and 24 months. Logistic regression was used to evaluate the association between predictor variables and adalimumab retention rate.Results: From 424 patients (53.5% male, aged 48.3 ± 12.8 years) who started treatment with adalimumab, 367 (86.6%) maintained treatment for 12 months and 313 (73.8%) for 2 years. At 24-months, Disease Activity in PsA (DAPSA) remission (defined as ≤4) and Low Disease Activity (LDA) (≤14) were achieved in 22.8% and 44.4% of patients, respectively. Adalimumab treatment significantly decreased the number of tender (7.0 ± 5.7 at baseline vs. 2.3 ± 3.5 at 24 months, p < 0.001) and swollen joints (2.7 ± 2.8 at baseline vs. 0.4 ± 0.9 at 24 months, p < 0.001), DAPSA (25.5 ± 10.9 at baseline vs. 11.0 ± 8.4 at 24 months, p < 0.001), PASI (5.3 ± 5.7 at baseline vs. 2.7 ± 2.8 at 24 months, p < 0.001) and CRP (3.8 ± 6.3 at baseline vs. 1.2 ± 1.7 at 24 months, p < 0.001). Among a range of laboratory and clinical variables, only female gender was associated with improved adalimumab persistence at 24 months (OR: 1.98, 95% CI: 1.2–3.2, p = 0.005).Conclusions: Independent of a range of predictor variables, adalimumab was shown to be effective, while maintaining a high retention rate after 2 years in PsA patients.
Highlights
Psoriatic arthritis (PsA) is a chronic and invalidating disease characterized by joint and entheseal inflammation affecting 0.05– 0.25% of the general population and 6–41% of patients with psoriasis (Gottlieb and Dann, 2009; Laws et al, 2010; Olivieri et al, 2014; Ogdie and Weiss, 2015).Up until two decades ago, treatment of PsA was often unsatisfactory
Among a range of laboratory and clinical variables, only female gender was associated with improved adalimumab persistence at 24 months (OR: 1.98, 95% CI: 1.2–3.2, p = 0.005)
Findings based on the immunopathogenesis of the disease have led to the development of biological drugs directed against specific targets, in particular tumor necrosis factor-a (TNFa)
Summary
Psoriatic arthritis (PsA) is a chronic and invalidating disease characterized by joint and entheseal inflammation affecting 0.05– 0.25% of the general population and 6–41% of patients with psoriasis (Gottlieb and Dann, 2009; Laws et al, 2010; Olivieri et al, 2014; Ogdie and Weiss, 2015).Up until two decades ago, treatment of PsA was often unsatisfactory. Psoriatic arthritis (PsA) is a chronic and invalidating disease characterized by joint and entheseal inflammation affecting 0.05– 0.25% of the general population and 6–41% of patients with psoriasis (Gottlieb and Dann, 2009; Laws et al, 2010; Olivieri et al, 2014; Ogdie and Weiss, 2015). Anti-TNFa drugs have opened new therapeutic horizons in PsA, proving to be effective in the control of the signs/symptoms of inflammation, in improving the quality of life and the functional outcome, in inhibiting the progression of the structural damage in the peripheral joints and presenting a good safety profile (D'Angelo et al, 2012; Perrotta and Lubrano, 2016; D'Angelo et al, 2017). Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA)
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call